GEN Exclusives

More »

The Lists

More »
Dec 4, 2012

25 Diabetes Drugs in the Pipeline Right Now

Meet the new weapons in the war against the chronic metabolic disease.

25 Diabetes Drugs in the Pipeline Right Now

These drugs may hit the market in the near future as potential treatments for diabetes. [Celso Pupo - Fotolia.com]

  • If diabetes were a stock, it'd be booming: the CDC says that the number of people with diagnosed diabetes has increased by 373% over the past 30 years, from 5.6 million in 1980 to 20.9 million in 2011. What new medicines are coming out to help turn diabetes' boom into a bust?

    You've seen GEN's list of 15 breast cancer drugs that are currently in the pipeline; now, GEN has compiled a list of 25 drug candidates for which diabetes is at least one proposed or approved indication, and for which one indication has reached Phase III or Registration phases. Each entry includes the name of the drug candidate, the sponsor, and, where applicable, collaboration partners; method of action; indication (by market, where applicable); and phase of trial. Some products are still in clinical trial phases for new indications or formulations after winning marketing approval for initial indications; these approvals, where applicable, are listed on the bottom of each entry.

  • Albiglutide (formerly Syncria)

    Sponsor/Developer: GlaxoSmithKline; developed by Human Genome Sciences, which licensed the drug for late-stage trials before Glaxo acquired HGS in a $3 billion deal completed Aug. 3

    Mechanism of action: Glucagon-like peptide (GLP) 1 agonist

    Indication (Phase): Once-weekly for type 2 diabetes (Phase III completed; NDA expected to be filed early 2013)

  • Alogliptin (Nesina®)

    Sponsor/Developer: Takeda Pharmaceuticals and Furiex Pharmaceuticals

    Mechanism of action: DPP-4 inhibitor

    Indication (Phase): U.S.—Oral treatment of type 2 diabetes, individually and as a fixed-dose combination (FDC) with the thiazolidinedione pioglitazone (Registration; NDA re-submitted July 2012 after initial NDA rejected via complete response letter April 2012)

    EU—Oral treatment of type 2 diabetes (Registration; MAA submission accepted May 2012)

    Japan—Marketed as Nesina®; Approved 2011 for oral treatment of type 2 diabetes as FDC with pioglitazone; Approved 2010 for oral treatment of type 2 diabetes

  • ASP1941 (ipragliflozin)

    Sponsor/Developer: Astellas; co-developed with Kotobuki

    Mechanism of action: Sodium dependent glucose transporter 2 (SGLT2) inhibitor

    Indication (Phase): Japan—Type 2 diabetes with inadequate glycemic control while on a sulfonylurea or pioglitazone alone (Phase III)

    U.S. and EU—Development discontinued “after comprehensive consideration of intensified competition for this product, and the prioritization in our pipeline”

  • Canagliflozin

    Sponsor/Developer: Johnson & Johnson (Janssen Research & Development); licensed from Mitsubishi Tanabe Pharma

    Mechanism of action: SGLT2 inhibitor

    Indication (Phase): U.S.—Once-daily oral treatment for adults with type 2 diabetes (registration; NDA filed May 2012)

    EU—Once-daily oral treatment for adults with type 2 diabetes (registration; MAA filed June 2012)

  • Darapladib (SB-480848)

    Sponsor/Developer: GlaxoSmithKline; developed by Human Genome Sciences, which licensed the drug for late-stage trials before Glaxo acquired HGS in a $3 billion deal completed Aug. 3.

    Mechanism of action: Lp-PLA2 inhibitor

    Indication (Phase): U.S.—Diabetic macular edema (DME; Phase II as of July 2012; expected to be completed December 2012); Atherosclerosis (Phase III; AIM III study recruiting patients as of November 2012); Atherosclerosis (Phase III; ongoing but not recruiting patients); Chronic coronary heart disease (Phase III; STABILITY trial, ongoing but not recruiting patients as of November); Cardiovascular event (heart attack or stroke) within 30 days after an acute coronary syndrome (Phase III; ongoing but not recruiting as of November 2012); Severe renal impairment (Phase I; recruiting as of November 2012)

    EU—DME (Phase II)

  • Dulaglutide (LY2189265)

    Sponsor/Developer: Eli Lilly

    Mechanism of action: GLP-1 analog

    Indication (Phase): Once-weekly, for type 2 diabetes (Phase III; results from three of five AWARD trials released Oct. 22; AWARD 2 and 4 results to be released “in the next few months”; major cardiovascular events and other serious outcomes in persons with type 2 diabetes (Phase III; REWIND trial, recruiting as of November 2012); Type 2 diabetes compared with glimepiride, liraglutide, insulin glargine (Phase III; recruiting as of November 2012); Japanese participants with type 2 diabetes, with monotherapy of oral antihyperglycemic medications (Phase III; recruiting as of November 2012); Chinese participants with type 2 diabetes (Phase III; recruiting as of November 2012)

    NDA to be submitted in 2013

  • Empagliflozin (BI10773)

    Sponsor/Developer: Eli Lilly and Boehringer Ingelheim

    Mechanism of action: SGLT 2 inhibitor

    Indication (Phase): Oral treatment of adults with type 2 diabetes (Phase III, expected to conclude by year’s end); Oral treatment of adults with type 2 diabetes plus high blood pressure (Phase IIb; trial results released Oct. 2)

    NDA, MAA filings planned for 2013

  • Forxiga™ (dapagliflozin)

    Sponsor/Developer: Bristol-Myers Squibb and AstraZeneca

    Mechanism of action: SGLT2 inhibitor

    Indication (Phase): EU—Approved Nov. 14 as once-daily oral medication for adults with type 2 diabetes; first SGLT2 drug to gain such approval

    U.S.—Once-daily oral medication for adults with type 2 diabetes (Registration; FDA in October 2012 postpones decision three months pending submission of additional clinical trial data; complete response letter issued January 2012; FDA Endocrinologic and Metabolic Drugs Advisory Committee recommends against approval, July 2011; NDA filed March 2011)

    Japan—Diabetes (Registration; NDA expected to be filed in first half of 2013)

  • IDegLira (NN9068)

    Sponsor/Developer: Novo Nordisk

    Mechanism of action: Combination of Tresiba® (insulin degludec) and Victoza® (liraglutide)

    Indication (Phase): Type 2 diabetes (Phase IIIa; DUAL II study, expected to be completed by year’s end); Type 2 diabetes in patients previously inadequately controlled on one or two oral anti-diabetic drugs (Phase IIIa; DUAL I study, results released August 2012)

  • Lantus® (insulin glargine)

    Sponsor/Developer: Sanofi

    Mechanism of action: Human insulin analog

    Indication (Phase): U.S.—Prediabetes or early type 2 diabetes with high cardiovascular risk (Phase III; ORIGIN study; results announced Oct. 5); Approved for adults and children with type 1 diabetes, and adults with type 2 diabetes

    EU—On May 25, European Commission approved changing the indication to “Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above,” from “treatment of adults, adolescents and children of 6 years or above with diabetes mellitus, where treatment with insulin is required”

  • Lyxumia® (lixisenatide; AVE0010)

    Sponsor/Developer: Sanofi; in-licensed from Zealand Pharma

    Mechanism of action: GLP-1 agonist

    Indication (Phase): U.S.—Once-daily, for adults with type 2 diabetes with oral glucose-lowering medicinal products and/or basal insulin (Phase III results announced June 2012; NDA expected by year’s end)

    EU—Once-daily, for adults with type 2 diabetes with oral glucose-lowering medicinal products and/or basal insulin (Registration; MAA submitted November 2011; recommended for approval by Committee for Medicinal Products for Human Use (CHMP) on Nov. 15)

  • LY2605541

    Sponsor/Developer: Eli Lilly and Boehringer Ingelheim

    Mechanism of action: Basal insulin analog

    Indication (Phase): Adults with type 1 diabetes, compared with insulin glargine and insulin lispro (Phase III; IMAGINE 1 study; ongoing but not recruiting as of November 2012); Adults with type 1 diabetes, compared with insulin glargine and insulin lispro (Phase III; IMAGINE 3 study; recruiting as of November 2012); Adults with type 2 diabetes, compared with insulin glargine and insulin lispro (Phase III; IMAGINE 4 study; recruiting as of November 2012); Adults with type 2 diabetes, compared with insulin glargine (Phase III; IMAGINE 2 and IMAGINE 5 studies; recruiting as of November 2012); Adults with type 1 diabetes, compared with insulin glargine (Phase I); Patient reported results from Phase II announced Oct. 2


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?